Texas Medical Cannabis Program Broadens Access
Texas public safety officials have granted tentative approval to 12 additional cannabis providers, marking a significant expansion of the state’s medical cannabis program. This development follows a legislative decision last year to increase the number of licensed operators from three to a maximum of 15, according to state officials.
The Texas Department of Public Safety (DPS), which oversees the state’s Compassionate Use Program (CUP), released an initial list of nine conditionally approved applicants in December. The updated list, finalized on a recent Friday, now includes 12 companies. When these licenses are fully approved, they will permit the selected businesses, many of which are Texas-based, to cultivate, manufacture, store, and distribute medical cannabis throughout the state. DPS officials stated that additional due diligence evaluations are required before final invoicing of dispensing organization license fees.
New Licensees and Operational Requirements
The 12 companies conditionally approved to join the Texas medical cannabis program span various regions, aiming to establish a statewide network. These include:
- Verano Texas LLC (El Paso region)
- Trulieve TX Inc. (Panhandle)
- Texas Patient Access LLC (North Texas)
- Lonestar Compassionate Care Group LLC (North Texas)
- Lone Star Bioscience Inc. (San Antonio and Central Texas)
- PC TX OPCO LLC/PharmaCann (Houston area)
- Texa OP/TexaRx (Rio Grande Valley)
- Dilatso LLC (North Texas)
- Bluebonnet Technologies LLC (Houston area)
- Sawtooth Texas LLC (northeastern Piney Woods area)
- Bayou Medical Dispensary (Piney Woods area)
- GTI Texas, LLC dba RISE Dispensaries (West Texas)
Under the new legislation, these entities must commence operations within two years of receiving their final approval. Texas currently has three existing licensees in its decade-old program, with two actively dispensing: Texas Original in Austin and GoodBlend in Plano, which recently began on-site dispensing under the updated regulations. The DPS adjusted the list of conditional licensees after identifying incorrect tabulations in the evaluation process, moving three companies (Story of Texas LLC, Texas Medica Collective, and Cresco Labs Texas) to a waiting list for future openings.
Program Enhancements and Industry Perspectives
The recent legislative changes, passed with near-unanimous approval, represent the most substantial expansion of medical cannabis access in Texas to date. Key provisions include:
- An increase in the allowable concentration of tetrahydrocannabinol (THC) in medical products.
- Permission for patients to use inhalers or vaporizers for medication delivery.
- Expansion of qualifying conditions to include Crohn’s disease, other irritable bowel disorders, traumatic brain injuries, and chronic pain, in addition to previously covered conditions such as post-traumatic stress disorder and cancer.
These changes are expected to facilitate more dispensary and storage sites across Texas, potentially leading to reduced prices, faster deliveries, and more convenient patient pickups. However, some advocates suggest that the expanded program still has limitations. Concerns have been raised regarding the program’s scope compared to the availability of hemp-derived cannabinoids, including THC-A products, which some users report relying on for appetite, sleep, and anxiety, and which may face future restrictions. Additionally, the program does not currently provide official patient identification cards or legal protections for participants on probation or parole regarding drug test outcomes, aspects common in other medical cannabis systems.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
